<DOC>
	<DOCNO>NCT00002634</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy , radiation therapy , immunotherapy , bone marrow transplantation treat patient neuroblastoma .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Immunotherapy , Bone Marrow Transplantation Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Improve complete remission rate progression-free survival reduce relapse rate patient poor-risk neuroblastoma use intensive multimodality therapy : cyclophosphamide/doxorubicin/vincristine cisplatin/etoposide , external-beam radiotherapy , surgery ( feasible ) , follow radioimmunotherapy iodine I 131 label monoclonal antibody 3F8 follow autologous bone marrow transplant immunotherapy unlabeled 3F8 . II . Identify biologic clinical prognostic factor may guide future modification treatment approach malignancy . OUTLINE : Patients stratify prior therapy ( yes v ) . Patients undergo surgery either diagnosis least 4 course chemotherapy , possibly completion chemotherapy . Patients receive cyclophosphamide IV 6 hour day 1-2 , doxorubicin IV vincristine IV 72 hour day 1-3 course 1 , 2 , 4 , 6 . Cisplatin IV 1 hour day 1-4 vincristine IV 2 hour day 1-3 administered course 3 , 5 , 7 . Courses administer every 16-21 day . Autologous bone marrow collect 3 course chemotherapy provide marrow negative tumor cell . Patients undergo radiotherapy completion chemotherapy . Radiotherapy administer twice day 7 day . Patients receive iodine I 131 label monoclonal antibody 3F8 ( MOAB 3F8 ) day -5 day 1-5 . Autologous bone marrow reinfused day 5 filgrastim ( G-CSF ) administer IV subcutaneously begin day 6 . Patients develop HAMA allergy mouse proteins receive unlabeled MOAB 3F8 IV 1.5 hour , 5 day week 2 week . Treatment repeat every 1-2 month 4 course . Patients follow every month 2 year , every 3 month 1 year , annually thereafter . PROJECTED ACCRUAL : Up 45 newly diagnose patient accrue study within 5 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Neuroblastoma diagnose accordance International Neuroblastoma Staging system : Histologic confirmation MSKCC OR Elevated urinary catecholamine plus tumor cells/clumps bone marrow Stage IV Stage II/III 10 copy Nmyc protooncogene per tumor cell PATIENT CHARACTERISTICS : See General Eligibility Criteria PRIOR CONCURRENT THERAPY : Prior therapy allow Patient Characteristics Age : Over 1 year diagnosis Performance status : Not specify Hematopoietic : Absolute neutrophil count least 500/mm3 ( except case bone marrow infiltration tumor ) Platelet count least 100,000/mm3 ( except case bone marrow infiltration tumor ) Hepatic : Not specify Renal : Not specify Other : No history allergy mouse proteins Human antimouse antibody ( HAMA ) less 1,000 U/ml ( prior exposure murine antibody )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>